Skip to content

Psilocybin for end-of-life distress

Studies whose primary subject is both Psilocybin and End-of-life distress, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 23 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, End-of-life distress, existential distress, then ranked by relevance.

Psilocybin-assisted psychotherapy for end-of-life distress shows consistent, large reductions in depression, anxiety, demoralization, and death anxiety in cancer and palliative populations, with several trials reporting that benefits persist for months and, in one follow-up, up to 4.5 years. Evidence comes mostly from small trials and reviews, with few participants overall, limited blinding, and populations skewed toward healthier, white, and financially privileged patients. Access and implementation remain major barriers, and no study directly compares psilocybin against standard palliative treatments in a large, diverse sample.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 23 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer 2020 long-term within-subjects follow-up 15 Supports Reductions in anxiety, depression, hopelessness, demoralization, and death anxiety were sustained at 3.2 and 4.5 years, with 60-80% still meeting criteria for clinically significant antidepressant or anxiolytic response.
Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer 2021 RCT secondary analysis Supports Among participants with elevated baseline suicidal ideation, psilocybin-assisted psychotherapy was associated with within-group reductions in suicidal ideation from 8 hours through 6.5 months, and large reductions in loss of meaning persisted to 4.5 years.
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. 2022 review Supports Reports that one-time psychedelic-assisted therapy may produce sustained reductions in anxiety, depression, and demoralization in seriously ill and end-of-life patients, while noting limited practical guidance for clinicians.
The Potential of Psychedelics for End of Life and Palliative Care. 2022 review Supports Proposes that psychedelics may offer clinicians an additional psychopharmacological treatment for depression, existential distress, and well-being in end-of-life and palliative care.
Psilocybin in Palliative Care: An Update. 2023 review Supports Reports significant and sometimes sustained anxiolytic, antidepressant, anti-inflammatory, and entheogenic effects with a favorable safety profile, while noting selection bias and short follow-up as limitations.
Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application—a review 2024 narrative review Supports Psilocybin combined with psychotherapy has shown rapid and sustained reductions in existential and psychiatric distress in patients facing life-threatening illness.
Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review. 2025 systematic review Supports Across 14 studies, psilocybin therapy consistently reduced depression, anxiety, and existential distress, with improvements sustained over several months and generally mild, transient adverse effects.
Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease. 2025 review Supports Psychedelic-assisted therapy is associated with highly significant and sometimes sustained decreases in depression and death anxiety, along with improvements in meaning, spiritual well-being, and life satisfaction.
Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy 2025 systematic review 74 Supports Across six studies, psilocybin-assisted therapy produced clinically significant reductions in depression and anxiety, with 57-79% achieving at least 50% symptom reduction and improvements sustained up to 4.5 years, with no serious adverse events.
Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study. 2026 open-label pilot study 11 Supports A single 25 mg dose with multidisciplinary palliative care was safe and feasible, with 90% of dosed participants no longer meeting criteria for clinically significant demoralization by study endpoint.
PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial 2026 open-label single-arm trial 20 Supports Microdose psilocybin over three weeks was safe and feasible, with 69% of completers reporting meaningful global improvement and over half showing clinically significant reductions in depression and demoralization.
Meaning and Psychedelics in Palliative Care: A Narrative Review. 2026 narrative review Supports Loss of meaning is a hallmark of demoralization, and early clinical trial data suggest psychedelic therapies show promise for existential distress and demoralization in palliative care.
Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review 2026 narrative review Supports Psilocybin-assisted psychotherapy is described as a compelling therapeutic option warranting further rigorous, interdisciplinary research for ethically grounded implementation in palliative settings.
Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey 2024 cross-sectional survey 2800 Supports 79.3% considered psilocybin-assisted therapy a reasonable medical choice for existential distress at the end of life, and 84.8% agreed the public health system should cover its costs.
Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress 2024 pilot survey 31 Mixed 51.6% expressed interest in future psilocybin treatment while 32.3% did not, with concerns about psychosis risk, lack of trained providers, and potential for exploitation.
Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders 2026 cross-sectional survey 121 Supports 95% of physicians reported favorable attitudes toward psilocybin-assisted therapy, and 68% of stakeholders endorsed introducing it early in the illness trajectory, though lack of trained providers was the primary barrier.
Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions 2021 qualitative descriptive study 5 Mixed Providers described multiple barriers to addressing existential distress and expressed uncertainty about the risks and benefits of psilocybin.
What do health professionals think about implementing psilocybin-assisted therapy in palliative care for existential distress? A World Café qualitative study. 2024 qualitative study 16 Mixed Professionals considered psilocybin-assisted therapy a treatment of interest but raised concerns about training, legalization, protocols, and eligibility criteria that need to be addressed for acceptability and access.
The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer 2026 qualitative study 11 Mixed Professionals remained interested in psychedelic-assisted therapy for existential distress but identified knowledge gaps, barriers, and a need for more research, preferring multidisciplinary and culturally sensitive delivery.
Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis 2026 qualitative study 7 Supports Participants considered psilocybin a much-needed alternative to traditional treatments for cancer-related depression and anxiety but felt its legal status was a significant barrier to access.
Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation. 2026 single-case implementation study 10 Opposes Despite favorable views and modest estimated costs, no patients received psilocybin-assisted therapy after one year, indicating a gap between regulatory authorization and service uptake.
Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy 2025 descriptive study 10 Supports A decision aid for psilocybin-assisted therapy showed satisfactory acceptability and usability and met IPDAS criteria for supporting shared decision-making.
Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy. 2023 commentary Unclear Argues that hospice and palliative care models offer practical lessons for scaling human-centered psychedelic-assisted therapy, including interdisciplinary care and holistic approaches.

Points of agreement

  • Multiple trials and reviews report large reductions in depression, anxiety, demoralization, and death anxiety after psilocybin-assisted psychotherapy in cancer and palliative populations.
  • Several sources report that benefits persist for months, with one follow-up finding sustained responses up to 4.5 years.
  • Adverse effects are generally described as mild and transient, with no serious adverse events reported in the trials reviewed.
  • Stakeholder surveys and qualitative studies find substantial interest in psilocybin-assisted therapy among patients, clinicians, and the public.
  • Reviews consistently note that loss of meaning and demoralization are key treatment targets and that psilocybin may enhance meaning-making.

Conflicts

  • Clinical trials and reviews report positive efficacy, while implementation research found that no patients received therapy in the first year despite favorable attitudes.
  • Some clinician and patient samples express uncertainty or concerns about risks, contrasting with the more uniformly positive framing in reviews.
  • Microdose and single high-dose protocols are both reported as beneficial, but no study directly compares them.

Gaps

  • Most trials are small, and total participants across reviewed studies are few.
  • Blinding is difficult and several studies are open-label or unblinded.
  • Populations skew toward healthier, white, and financially privileged patients, limiting generalizability.
  • Follow-up beyond a few years is limited, and durability of benefit is not well established.
  • Optimal dose, protocol, and psychotherapy components are not established.
  • Implementation barriers, training needs, and access inequities are largely unaddressed by efficacy research.
Browse these studies in the library

Common questions

What does the research agree on about psilocybin for end-of-life distress?
  • Multiple trials and reviews report large reductions in depression, anxiety, demoralization, and death anxiety after psilocybin-assisted psychotherapy in cancer and palliative populations.
  • Several sources report that benefits persist for months, with one follow-up finding sustained responses up to 4.5 years.
  • Adverse effects are generally described as mild and transient, with no serious adverse events reported in the trials reviewed.
  • Stakeholder surveys and qualitative studies find substantial interest in psilocybin-assisted therapy among patients, clinicians, and the public.
  • Reviews consistently note that loss of meaning and demoralization are key treatment targets and that psilocybin may enhance meaning-making.
Where do studies on psilocybin for end-of-life distress conflict?
  • Clinical trials and reviews report positive efficacy, while implementation research found that no patients received therapy in the first year despite favorable attitudes.
  • Some clinician and patient samples express uncertainty or concerns about risks, contrasting with the more uniformly positive framing in reviews.
  • Microdose and single high-dose protocols are both reported as beneficial, but no study directly compares them.
What is still unknown about psilocybin for end-of-life distress?
  • Most trials are small, and total participants across reviewed studies are few.
  • Blinding is difficult and several studies are open-label or unblinded.
  • Populations skew toward healthier, white, and financially privileged patients, limiting generalizability.
  • Follow-up beyond a few years is limited, and durability of benefit is not well established.
  • Optimal dose, protocol, and psychotherapy components are not established.
  • Implementation barriers, training needs, and access inequities are largely unaddressed by efficacy research.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Psilocybin for end-of-life distress, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Psilocybin for end-of-life distress or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

38 articles · 21 from the last two years · 3,251 participants across 18 studies reporting sample size

Common study designs

review 11 commentary 2 narrative review 3 qualitative study 6 systematic review 3

Research volume by year

Compare topics →

37 studies whose primary subject is psilocybin for end-of-life distress since 2020

Studies about psilocybin for end-of-life distress per year, 2020 to 2026, peaking at 12 in 2025 Bar chart: one bar per year, taller where more studies were published that year. 0 10 20 2020 2025
2026 is partial
Show the numbers
Studies about psilocybin for end-of-life distress per year, 2020 to 2026, peaking at 12 in 2025
Year Studies
2020 1
2021 3
2022 4
2023 3
2024 5
2025 12
2026 9

Research

Synthesize the evidence →

Psilocybin-Assisted Therapy for Cancer-Related Psychological and Existential Distress in Adults with Cancer: An Integrative Systematic Review

Journal of Pain & Palliative Care Pharmacotherapy November 3, 2026 Athanasios Pitis, Maria Nikoloudi, Nikos C. Stefanis et al.

Psilocybin-assisted therapy has reemerged as a promising intervention for distress associated with cancer and life-threatening illness. This integrative systematic review evaluated evidence on the safety, efficacy, and therapeutic impact of psilocybin-assisted therapy in adults with cancer experiencing depression, anxiety and existential distress. Following PRISMA guidelines, PubMed, Scopus,...

DOI: 10.1080/15360288.2026.2756950 (opens in new tab)

Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study.

medRxiv July 14, 2026 Ali J Zarrabi, Tanja Mletzko, George H. Grant et al. preprint

Demoralization, a syndrome of helplessness, hopelessness, and loss of meaning and chronic pain are common sources of distress in early palliative care. Psilocybin-assisted therapy (PAT) is an emerging intervention with preliminary data suggesting improvements in pain and demoralization. To date, PAT has not been studied among people living with both demoralization and chronic pain nor has it...

DOI: 10.64898/2026.07.11.26357570 (opens in new tab) Full text (opens in new tab)

The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer

BMC Medicine July 6, 2026 Hannah Adler, Rebecca Filipic, Dr Maria Gonzalez et al.

BACKGROUND: Existential distress is commonly experienced by people with cancer, yet there are limited treatment options. The therapeutic potential for psychedelic-assisted therapy (PAT) utilising psilocybin for this cohort is underexplored, with emerging literature showing clinical improvements in wellbeing. In Australia there is limited knowledge on healthcare professionals' (HCPs') attitudes,...

DOI: 10.1186/s12916-026-05024-2 (opens in new tab) Psilocybin Existentialism Distress Thematic analysis +12

Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation.

Healthcare June 3, 2026 Michel Dorval, Virginie Audet-Croteau, Sue-Ling Chang et al.

Background/Objectives: Psilocybin-assisted therapy (PAT) is a promising intervention to alleviate existential distress among patients with advanced cancer receiving palliative care. However, evidence on how to integrate PAT into routine oncology and palliative care services remains scarce. This study aimed to examine real-world PAT implementation, identify factors influencing adoption, and...

DOI: 10.3390/healthcare14111559 (opens in new tab) Full text (opens in new tab) Existential distress Cost analysis Implementation Palliative care +2

Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders

Palliative Medicine May 19, 2026 Louis Plourde, Sue-Ling Chang, Olivia Nguyen et al. 1 citation

BACKGROUND: While the adoption of psilocybin-assisted therapy for existential distress offers promising support for patients with life-threatening illnesses, implementing this intervention into palliative care settings presents significant real-world challenges. AIM: To examine palliative care stakeholders' knowledge and attitudes regarding psilocybin-assisted therapy, and identify barriers and...

DOI: 10.1177/02692163261446141 (opens in new tab)

Meaning and Psychedelics in Palliative Care: A Narrative Review.

Journal of Pain and Symptom Management March 1, 2026 William B Alexander, Eric D Hansen, Brian T Anderson et al. 1 citation

Meaning is a primary existential concern in those with advanced illnesses and functions as an important coping mechanism. Loss of meaning contributes to existential distress, and, in particular, may manifest as demoralization, a syndrome of poor coping that is associated with negative outcomes. Psychedelics are unique psychoactive compounds that, among other properties, are proposed to enhance...

DOI: 10.1016/j.jpainsymman.2025.10.015 (opens in new tab) Full text (opens in new tab) LSD Existential distress Palliative Psilocybin +3

Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review

BMJ Supportive & Palliative Care February 18, 2026 Luca Magnani, Luca Ghirotto, Fabio Fesce et al.

psilocybin-assisted psychotherapy is a compelling therapeutic option warranting further investigation through rigorous, interdisciplinary research to promote an anthropologically/ethically grounded implementation in palliative settings, even beyond the oncology field.

DOI: 10.1136/spcare-2025-005689 (opens in new tab) Psychotherapist Narrative review Psycho-oncology Palliative care +6

Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis

Qualitative Health Research February 17, 2026 Zaynab Khan, Sterre Weaver, Rachael V. Dando et al. 1 citation

People with cancer often experience anxiety and depression following a diagnosis and can face barriers to accessing treatment for their mental health. An increasing number of patients are considering alternative approaches to managing their mental health symptoms, such as the psychedelic, psilocybin. A growing number of clinical trials show significant and enduring improvements in mood and...

DOI: 10.1177/10497323261419338 (opens in new tab) Psilocybin Anxiety Mindfulness Interpretative phenomenological analysis +13

PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial

Palliative Medicine January 30, 2026 James Downar, Julie Lapenskie, Koby Anderson et al.

Background: Psychological distress is a common problem near the end of life, for which we lack effective, timely and scalable treatments. No previous study has assessed whether microdose psilocybin can improve symptoms in this population. Aim: To determine whether microdose psilocybin is safe, feasible and potentially efficacious in a palliative setting. Design: Open label, single-arm clinical...

DOI: 10.1177/02692163261416269 (opens in new tab) Psilocybin Palliative care Clinical trial Microdose +8

Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy

Palliative Medicine December 18, 2025 Rita S. Matos, A. C. Silva, Licínio Rego et al. 1 citation

Background: Palliative Care is concerned with relieving suffering and improving the quality of life of patients and their families. Currently, questions arise about how to provide patients with good end-of-life care. There has been increasing interest in the beneficial effects of using psilocybin-assisted therapy in patients with severe chronic illnesses near the end of their lives and who...

DOI: 10.1177/02692163251383335 (opens in new tab) Anxiety Palliative care Health care Medline +4

Clinical trials

All psilocybin for end-of-life distress trials →